Compare ARCB & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCB | SUPN |
|---|---|---|
| Founded | 1923 | 2005 |
| Country | United States | United States |
| Employees | 14000 | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.8B |
| IPO Year | 1994 | 2010 |
| Metric | ARCB | SUPN |
|---|---|---|
| Price | $141.12 | $43.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $122.75 | $61.60 |
| AVG Volume (30 Days) | 232.3K | ★ 581.4K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,657,864,000.00 | $392,755,000.00 |
| Revenue This Year | $7.00 | $22.70 |
| Revenue Next Year | $5.80 | $19.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.56 | N/A |
| 52 Week Low | $59.43 | $42.45 |
| 52 Week High | $176.69 | $59.68 |
| Indicator | ARCB | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 41.02 |
| Support Level | $134.67 | $44.09 |
| Resistance Level | $148.59 | $52.33 |
| Average True Range (ATR) | 5.68 | 1.30 |
| MACD | -0.06 | -0.29 |
| Stochastic Oscillator | 35.69 | 19.63 |
ArcBest Corp is an integrated logistics company that leverages technology and a full suite of shipping and logistics solutions to meet customers' supply chain needs. The company has two reportable operating segments: Asset-Based, which generates maximum revenue, and Asset-Light. The Asset-Based segment's operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed less-than-truckload services. The Asset-Light segment represents the company's offerings in ground expedite, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.